Document is current
Any future updates will be listed below
-
Authors
Díaz, Luis Antonio https://orcid.org/0000-0002-8540-4930
Lazarus, Jeffrey V. https://orcid.org/0000-0001-9618-2299
Fuentes-López, Eduardo https://orcid.org/0000-0002-0141-0226
Idalsoaga, Francisco
Ayares, Gustavo
Desaleng, Hailemichael
Danpanichkul, Pojsakorn
Cotter, Thomas G.
Dunn, Winston
Barrera, Francisco
Wijarnpreecha, Karn
Noureddin, Mazen
Alkhouri, Naim
Singal, Ashwani K.
Wong, Robert J.
Younossi, Zobair M.
Rinella, Mary E.
Kamath, Patrick S.
Bataller, Ramon
Loomba, Rohit
Arrese, Marco
Arab, Juan Pablo https://orcid.org/0000-0002-8561-396X
- License Information
-
More Information
Article History
Received: 12 February 2024
Accepted: 17 October 2024
First Online: 29 October 2024
Competing interests
: Rohit Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. Rohit Loomba has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Rohit Loomba is a co-founder of LipoNexus Inc. Other authors declare that they have no conflicts of interest.
